UBS Group
CGEM icon

UBS Group’s Cullinan Oncology CGEM Stock Holding History

UBS Group’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.53M Buy
248,627
+46,242
+23% +$687K ﹤0.01% 4266
2026
Q1 		$2.88M Sell
202,385
-69,351
-26% -$891K ﹤0.01% 4625
2025
Q4 		$2.81M Buy
271,736
+83,551
+44% +$754K ﹤0.01% 4637
2025
Q3 		$1.12M Sell
188,185
-123,124
-40% -$902K ﹤0.01% 5478
2025
Q2 		$2.34M Buy
311,309
+32,490
+12% +$261K ﹤0.01% 4649
2025
Q1 		$2.11M Buy
278,819
+43,106
+18% +$414K ﹤0.01% 4658
2024
Q4 		$2.87M Buy
235,713
+50,160
+27% +$721K ﹤0.01% 4374
2024
Q3 		$3.11M Buy
185,553
+25,573
+16% +$454K ﹤0.01% 3547
2024
Q2 		$2.79M Sell
159,980
-6,760
-4% -$144K ﹤0.01% 3420
2024
Q1 		$2.84M Buy
166,740
+25,961
+18% +$401K ﹤0.01% 3590
2023
Q4 		$1.43M Buy
140,779
+37,316
+36% +$331K ﹤0.01% 4162
2023
Q3 		$936K Buy
103,463
+12,396
+14% +$129K ﹤0.01% 4129
2023
Q2 		$980K Sell
91,067
-9,985
-10% -$106K ﹤0.01% 4267
2023
Q1 		$1.03M Buy
101,052
+2,899
+3% +$32K ﹤0.01% 4069
2022
Q4 		$1.04M Buy
98,153
+7,086
+8% +$86.1K ﹤0.01% 4040
2022
Q3 		$1.17M Sell
91,067
-709
-0.8% -$9.55K ﹤0.01% 3625
2022
Q2 		$1.18M Sell
91,776
-33,133
-27% -$376K ﹤0.01% 3604
2022
Q1 		$1.31M Buy
124,909
+103,167
+475% +$1.39M ﹤0.01% 3841
2021
Q4 		$336K Buy
21,742
+17,749
+445% +$354K ﹤0.01% 5288
2021
Q3 		$90K Buy
3,993
+2,027
+103% +$54.2K ﹤0.01% 5900
2021
Q2 		$50K Sell
1,966
-1,127
-36% -$34.7K ﹤0.01% 6427
2021
Q1 		$129K Buy
+3,093
New +$126K ﹤0.01% 5759

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

UBS Group's CGEM Position: Q2 2026 in Review

UBS Group increased its Cullinan Oncology (CGEM) stake by 23% in Q2 2026, buying an estimated $687K and bringing the position to 248,627 shares worth $4.53M. The position accounts for ﹤0.01% of the portfolio, ranked #4266.

UBS Group first reported a position in CGEM in Q1 2021 and has held it in 22 quarters since. 183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • UBS Group held 248,627 shares of Cullinan Oncology worth $4.53M as of Q2 2026.
  • UBS Group bought 46,242 Cullinan Oncology shares in Q2 2026, an estimated $687K.
  • Cullinan Oncology made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4266 holding.
  • UBS Group first reported a position in Cullinan Oncology in Q1 2021 and has held it in 22 quarters since.
  • 183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.